General Information of This Drug (ID: DMABVE9)

Drug Name
Sulfanilamide   DMABVE9
Synonyms
AAS; AVC; Albexan; Albosal; Ambeside; Antistrept; Astreptine; Astrocid; Bactesid; Collomide; Colsulanyde; Copticide; Deseptyl; Desseptyl; Dipron; Ergaseptine; Gerison; Gombardol; Infepan; Lusil; Lysococcine; Neococcyl; Orgaseptine; PABS; Prontalbin; Prontylin; Proseptal; Proseptine; Pysococcine; SAN; Sanamid; Septanilam; Septolix; Septoplex; Septoplix; Solfanilamide; Stramid; Strepamide; Streptagol; Streptamid; Streptocid; Streptocide; Streptocidum; Streptocom; Streptol; Strepton; Streptopan; Streptrocide; Sulfanilamida; Sulfanilamidum; Sulfocidin; Therapol; Tolder; Prontosil I; Prontosil White; Pronzin Album; Rubiazol A; Septamide Album; Solfanilamide [DCIT]; Stopton Album; Streptocid album; Streptocide White; Sulfanilamide Vaginal Cream; Sulphanilamide Extra Pure; Sulphanilamide Gr; White streptocide; F 1162; Fourneau 1162; Ro13354; A-349; AVC (TN); Aromatic/heteroaromatic sulfonamide 2; F-1162; P-Aminobenzenesulfonylamide; P-Aminobenzensulfonamide; Streptocid (TN); Streptocide (VAN); Sulfanilamida [INN-Spanish]; Sulfanilamide (INN); Sulfanilamide [INN:DCF]; Sulfanilamidum [INN-Latin]; Aniline-p-sulfonic amide; I.C. 56; BENZENESULFONIC ACID,4-AMINO,AMIDE SULFANILAMIDE; N4,N4-Bis(2-bromoethyl)sulfanilamide; N(sup 4),N(sup 4)-Bis(2-bromoethyl)sulfanilamide; N(sup4),N(sup4)-Bis(2-bromoethyl)sulfanilamide; Benzenesulfonamide, 4-(bis(2-bromoethyl)amino)-(9CI); Sulfanilamide, N4,N4-bis(2-bromoethyl)-(8CI); 1162 F; 4-(Bis(2-bromoethyl)amino)benzenesulfonamide; 4-Aminobenzene-1-Sulfonamide; 4-Aminophenylsulfonamide; 4-Sulfamoylaniline; 4-[bis(2-bromoethyl)amino]benzenesulfonamide
Indication
Disease Entry ICD 11 Status REF
Bacterial infection 1A00-1C4Z Approved [1]
Therapeutic Class
Antibiotics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

4 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
Sulfanilamide + Ruxolitinib DC5EZ5F Ruxolitinib Hodgkin lymphoma (Cell Line: L-1236) [2]
Sulfanilamide + Panobinostat DCOMDMC Panobinostat Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [2]
Sulfanilamide + Marizomib DC2UHFC Marizomib Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [2]
Sulfanilamide + Idarubicin DC5AZOF Idarubicin Glioblastoma? (Cell Line: T98G) [2]
------------------------------------------------------------------------------------

References

1 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 088718.
2 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.